While the latest Phase 2b trial in the GLP-1RA drug met its primary endpoint of showing statistically significant change in body weight from baseline, the pharma said that it will still discontinue the program
Today, people are more focused on their health, skin, and immunity
Schlow Centre Region Library
Tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 receptor agonist (GLP-1 RA), has shown superior efficacy in glycemic control, weight loss and cardiometabolic outcomes compared to GLP-1 agonists alone
One GLP-1 drug, known as albiglutide, which was withdrawn from the market with only a modest effect on weight loss, nonetheless reduced the rates of major adverse cardiovascular events by 22%